A Consensus Statement on acromegaly therapeutic outcomes

作者：Melmed, Shlomo^*; Bronstein, Marcello D.; Chanson, Philippe; Klibanski, Anne; Casanueva, Felipe F.; Wass, John A. H.; Stra**urger, Christian J.; Luger, Anton; Clemmons, David R.; Giustina, Andrea

来源：Nature Reviews Endocrinology, 2018, 14(9): 552-561.

DOI：10.1038/s41574-018-0058-5

• SOMATOSTATIN ANALOG THERAPY
• GROWTH-FACTOR-I
• ENDOSCOPIC TRANSSPHENOIDAL SURGERY
• CARDIOVASCULAR RISK-FACTORS
• BONE-MINERAL DENSITY
• LONG-TERM TREATMENT
• PITUITARY-ADENOMAS
• FOLLOW-UP
• INSULIN SENSITIVITY
• VERTEBRAL FRACTURES

The 11th Acromegaly Consensus Conference in April 2017 was convened to update recommendations on therapeutic outcomes for patients with acromegaly. Consensus guidelines on the medical management of acromegaly were last published in 2014; since then, new pharmacological agents have been developed and new approaches to treatment sequencing have been considered. Thirty-seven experts in the management of patients with acromegaly reviewed the current literature and assessed changes in drug approvals, clinical practice standards and clinical opinion. They considered current treatment outcome goals with a focus on the impact of current and emerging somatostatin receptor ligands, growth hormone receptor antagonists and dopamine agonists on biochemical, clinical, tumour mass and surgical outcomes. The participants discussed factors that would determine pharmacological choices as well as the proposed place of each agent in the guidelines. We present consensus recommendations highlighting how acromegaly management could be optimized in clinical practice.

• 出版日期2018-9